NDATOPICALOINTMENT
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
VUSION (miconazole nitrate, zinc oxide, white petrolatum) by Viatris (2) is [see ]. First approved in 2006.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VUSION is a topical ointment combining miconazole nitrate (antifungal), zinc oxide, and white petrolatum for the treatment of diaper dermatitis. The miconazole component provides antifungal activity, while zinc oxide and white petrolatum serve as adjunctive protective and moisturizing agents. The exact mechanism of the latter two components remains pharmacologically uncharacterized.
$0.035BPart D
LOE Approaching1.9 years to LOEWith only 48 Part D claims and $35K annual spending in 2023, this is a low-volume specialty product approaching loss of exclusivity, signaling a highly constrained team and limited commercial growth opportunity.
Mechanism of Action
[see ]. The mechanism of action of white petrolatum and zinc oxide for the adjunctive treatment of diaper dermatitis is unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on VUSION at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.